Eming, RüdigerRüdigerEmingRiaz, ShafaqShafaqRiazMüller, Eliane J.Eliane J.MüllerZakrzewicz, AnnaAnnaZakrzewiczLinne, UweUweLinneTikkanen, RitvaRitvaTikkanenZimmer, Christine LeaChristine LeaZimmerHudemann, ChristophChristophHudemann2024-11-212024-11-212024https://boris-portal.unibe.ch/handle/20.500.12422/189463Background Pemphigus vulgaris (PV) is a life-threatening autoimmune blistering disease caused mainly by IgG autoantibodies (auto-abs) against the cadherin-type adhesion molecules desmoglein (Dsg) 1 and 3. Pathogenic anti-Dsg3 auto-abs bind to different Dsg3 epitopes, leading, among others, to signalling that is involved in pathogenic events, such as Dsg3 depletion. As central tools in research on PV, a limited number of antibodies such as AK23 are frequently used by the autoimmune bullous disease community.Methods Previously, we have introduced a novel Dsg3 EC5-binding antibody termed 2G4 that may potentially serve as a superior tool for numerous PV related analysis. The purpose of this study was to develop a quality-controlled production and verification process that allows I) a continuous quality improvement, and II) a verified and comprehensible overall quality with regard to pathogenic antigen-specific binding in a variety of pemphigus assays for each batch production.Results Thus, a workflow based on a standardized operating procedure was established. This includes the verification of purity and in-vitro binding capacity (SDS-page, direct and indirect immunofluorescence) as primary parameters, and size analysis by mass-spectrometry and ex-vivo pathogenicity by monolayer dissociation assay.Conclusion We here present an extensive point-by-point quality controlled IgG production protocol, which will serve as a basis for a standardized antibody assessment in PV research.en2G4PVantibodyautoimmunitydesmoglein (Dsg)pemphigus vulgarisquality control600 - Technology::610 - Medicine & healtharticle10.48620/764813945017910.3389/fimmu.2024.1464881